These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 21807982)

  • 1. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.
    Hightower KE; Wang R; Deanda F; Johns BA; Weaver K; Shen Y; Tomberlin GH; Carter HL; Broderick T; Sigethy S; Seki T; Kobayashi M; Underwood MR
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4552-9. PubMed ID: 21807982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.
    DeAnda F; Hightower KE; Nolte RT; Hattori K; Yoshinaga T; Kawasuji T; Underwood MR
    PLoS One; 2013; 8(10):e77448. PubMed ID: 24146996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
    Nguyen HL; Ruxrungtham K; Delaugerre C
    Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
    Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
    Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
    Johnson BC; Métifiot M; Pommier Y; Hughes SH
    Antimicrob Agents Chemother; 2012 Jan; 56(1):411-9. PubMed ID: 22037850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
    Oliveira M; Mesplède T; Moïsi D; Ibanescu RI; Brenner B; Wainberg MA
    AIDS; 2015 Nov; 29(17):2255-60. PubMed ID: 26372484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
    AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
    Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Group O Resistance Against Integrase Inhibitors.
    Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.
    Underwood MR; Johns BA; Sato A; Martin JN; Deeks SG; Fujiwara T
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):297-301. PubMed ID: 22878423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
    Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
    Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
    J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).
    Hare S; Smith SJ; Métifiot M; Jaxa-Chamiec A; Pommier Y; Hughes SH; Cherepanov P
    Mol Pharmacol; 2011 Oct; 80(4):565-72. PubMed ID: 21719464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
    You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M
    PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
    Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
    J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.